Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (Mpro) of SARS-CoV-2

Abstract

The spread of novel coronavirus SARS-CoV-2 has directed to a state of an unprecedented global pandemic. Many synthetic compounds and FDA-approved drugs have been significantly inhibitory against the virus, but no SARS-CoV-2 solution has been identified. However, small molecule fragment–based derivatives of potent phytocompounds may serve as promising inhibitors against SARS-CoV-2. In the pursuit of exploring novel SARS-CoV-2 inhibitors, we generated small molecule fragment derivatives from potent phytocompounds using neural networking and machine learning–based tools, which can cover unexplored regions of the chemical space that still retain lead-like properties. Out of 300 derivative molecules from withaferin-A, hesperidin, and baicalin, 30 were screened out with synthetic accessibility scores > 4 having the best ADME properties. The withaferin-A derivative molecules 61 and 64 exhibited a significant binding affinity of − 7.84 kcal/mol and − 7.94 kcal/mol. The docking study reveals that withaferin-A mol 61 forms 5 polar H-bonds with the M pro where amino acids involved are GLU166, THR190, CYS145, MET165, and GLN152 and upon QSAR analysis showed a minimal predicted IC50 value of 7762.47 nM. Furthermore, the in silico cytotoxicity predictions, pharmacophore modeling, and molecular dynamics simulation studies have resulted in predicting the highly potent small molecule derivative from withaferin-A (phytocompound from Withania somnifera ) to be the potential inhibitor of SARS-CoV 2 protease (M pro ) and a promising future lead candidate against COVID-19. The rationale of choosing withaferin-A from Withania somnifera (Ashwagandha) was propelled by the innumerous applications of Ashwagandha for the treatment of various antiviral diseases, common cold, and fever since time immemorial. Graphical abstract Supplementary Information The online version contains supplementary material available at 10.1007/s00894-021-04703-6.

Identification of Novel Gene Signatures using Next-Generation Sequencing Data from COVID-19 Infection Models: Focus on Neuro-COVID and Potential Therapeutics

“…In silico screening of several phytochemicals identified that Withanone, one of the constituents of ashwagandha, showed a potential inhibition of ACE2 ( Balkrishna et al, 2021 ). Additionally, Ghosh et al (2021) used molecular dynamic simulations and pharmacophore modeling approaches to predict the highly potent small-molecule derivative of withaferin A that potentially inhibits SARS-CoV-2 protease (Mpro), a favorable future therapeutic against COVID-19.…”

Alpha-glucosidase inhibitory activities of astilbin contained in Bauhinia strychnifolia Craib. stems: an investigation by in silico and in vitro studies

“…The coefficients A 1 through A n are derived by fitting the parameter and biological activity changes. These B 1 , B 2 , B 3 , etc., are the descriptor variables of the QSAR equation [ 28 ]. For this objective, molecular descriptors were derived using the SwissADME tool descriptor, and the experimental values of the training sample were obtained from a previous publication [ 29 ].…”

A machine learning regression model for the screening and design of potential SARS-CoV-2 protease inhibitors

“…Furthermore, the multiple linear regression model built in this study was formulated using at least 200 compounds. Some of the relevant MLR models have so far utilized 100 compounds or less (Amin et al 2021 ; De et al 2020 ; Ghosh et al 2021 ; Kumar and Roy 2020 ). Deep learning and other machine learning models can screen bigger number of compounds, but they lack interpretability, which highlights the simplicity, transparency and interpretability of MLR models.…”